FDA Approves Semaglutide to Prevent Heart Events in Patients With CVD and Excess Weight

Retrieved on: 2024-03-08 20:01:58

Tags for this article:

Click the tags to see associated articles and topics

FDA Approves Semaglutide to Prevent Heart Events in Patients With CVD and Excess Weight. View article details on hiswai:

Excerpt

1. FDA approves first treatment to reduce risk of serious heart problems specifically in adults with obesity or overweight. · 2. · 3.

Article found on: www.ajmc.com